Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3301392 Target Snapshot

JAK2/TYK2 · PROTEIN COMPLEX · Homo sapiens

56Compounds
27Assays
5Approved Drugs
69.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O60674. Use UniProt O60674 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O60674 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats JAK2/TYK2 as ChEMBL target CHEMBL3301392, mapped to UniProt O60674. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
JAK2/TYK2
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3301392
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O60674
Tyrosine-protein kinase JAK2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether JAK2/TYK2 is the right protein anchor across sources, using UniProt O60674 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase JAK2
UniProt AccessionO60674
Component TypeProtein
Sequence Length1132 aa

Tyrosine-protein kinase JAK2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as JAK2/TYK2, mapped to UniProt O60674. ChEMBL maps the protein component as Tyrosine-protein kinase JAK2. Sequence length is 1132 aa.

Mapped IDO60674
Review nameJAK2/TYK2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
1
Phase III
3
Phase II
Assay Mix

Activity Type Distribution

IC5068.0
EC501.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5418288 10.28 IC50 0.053 Preclinical
CHEMBL5420928 10.1 IC50 0.08 Preclinical
CHEMBL5413489 9.52 IC50 0.3 Preclinical
CHEMBL5440264 9.4 IC50 0.4 Preclinical
CHEMBL5420349 9.0 IC50 1.0 Preclinical
CHEMBL5422022 8.92 IC50 1.21 Preclinical
CHEMBL5416227 8.74 IC50 1.82 Preclinical
CHEMBL5397906 8.7 IC50 2.0 Preclinical
CHEMBL5441067 8.52 IC50 3.0 Preclinical
CHEMBL4548200 7.57 IC50 27.0 Preclinical
Distribution

pChEMBL Value Distribution

5
5.0
6
5.5
10
6.0
11
6.5
9
7.0
1
7.5
2
8.0
4
8.5
2
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

BARICITINIB
CHEMBL2105759
Approved 2017
TOFACITINIB
CHEMBL221959
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
Assay Landscape

Assay Landscape

27
Total Assays
49
Tested Compounds
1
Assay Types
Binding — 27 assays, 49 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 14 16 8.1
tissue-based format 7 2 6.5
protein complex format 5 7 5.9
assay format 1 24 6.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine